The University of Colorado and AmideBio LLC have executed an exclusive license agreement allowing the company to develop, manufacture and commercialize peptides based on the work of Michael Stowell, Ph.D., an associate professor of molecular, cellular and developmental biology at the University of Colorado at Boulder.
The CU technology is a method for manufacturing recombinant proteins and peptides (molecules similar to proteins but smaller). These types of molecules are often key for treating diseases that cannot be addressed using conventional chemical therapeutics, but the field has historically been limited by challenges such as economical manufacturing and delivery.
CU's technology circumvents these problems, particularly those associated with longer and more complex proteins, by leveraging a proprietary recombinant strategy that is economically viable and environmentally sustainable.
"We are pleased to be able to commercialize this technology developed at the University of Colorado, with which I have had an extensive and robust association," said Misha Plam, AmideBio president and CEO. "This advance in peptide manufacturing provides AmideBio with a real advantage in the market, by providing historically difficult-to-produce peptides, without compromising quality, yield or economics."
Tom Smerdon, director of licensing and new business development at the CU Technology Transfer Office, said, "We are pleased to see the launch of this new life science venture based on technology developed in Dr. Stowell's lab. We believe this technology has strong commercial potential, and AmideBio has the business leadership necessary to make it a commercial reality."